Dapagliflozin reduces hyperglycemia, body weight, and systolic blood pressure [17, 33] and increases atrial natriuretic peptide levels [34], which may contribute to the decrease in the incidence of cardiovascular disease (CVD). This evidence concerns the gene NPPA and Hyperglycemia.